Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O 6-benzylguanine to brain tumors

ACS Nano

Volumn 8, Issue 10, 2014, Pages 10383-10395

  Stephen, Zachary R ^a   Kievit, Forrest M ^b   Veiseh, Omid ^a   Chiarelli, Peter A ^b   Fang, Chen ^a,c   Wang, Kui ^a   Hatzinger, Shelby J ^b   Ellenbogen, Richard G ^b   Silber, John R ^b   Zhang, Miqin ^a,b  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

drug delivery; glioblastoma multiforme; iron oxide; nanomedicine; theranostic

Indexed keywords

BIOCOMPATIBILITY; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DRUG DELIVERY; IRON OXIDES; MAGNETIC NANOPARTICLES; MAMMALS; MEDICAL NANOTECHNOLOGY; PHYSICOCHEMICAL PROPERTIES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; THERANOSTICS; TOXICITY; TUMORS;

CONVECTION ENHANCED DELIVERIES (CED); CONVECTION-ENHANCED DELIVERY; COVALENT ATTACHMENT; DNA REPAIR PROTEINS; GLIOBLASTOMA MULTIFORME; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; THERANOSTIC; TUMOR TARGETING PEPTIDES;

TARGETED DRUG DELIVERY;

GUANINE; NANOPARTICLE; O(6)-BENZYLGUANINE;

ANALOGS AND DERIVATIVES; ANIMAL; BRAIN TUMOR; GLIOBLASTOMA; MAGNETISM; METABOLISM; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY;

ANIMALS; BRAIN NEOPLASMS; GLIOBLASTOMA; GUANINE; MAGNETIC RESONANCE IMAGING; MAGNETICS; MICE; MICE, NUDE; NANOPARTICLES; OXIDATION-REDUCTION;

EID: 84908440129     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn503735w     Document Type: Article

References (56)

1. Veiseh, O.; Kievit, F. M.; Ellenbogen, R. G.; Zhang, M. Cancer Cell Invasion: Treatment and Monitoring Opportunities in Nanomedicine Adv. Drug Delivery Rev. 2011, 63, 582-596
2. Kievit, F. M.; Zhang, M. Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery across Biological Barriers Adv. Mater. 2011, 23, H217-247
3. Veiseh, O.; Gunn, J. W.; Zhang, M. Design and Fabrication of Magnetic Nanoparticles for Targeted Drug Delivery and Imaging Adv. Drug Delivery Rev. 2010, 62, 284-304
4. Madabhushi, A.; Doyle, S.; Lee, G.; Basavanhally, A.; Monaco, J.; Masters, S.; Tomaszewski, J.; Feldman, M. Integrated Diagnostics: A Conceptual Framework with Examples Clin. Chem. Lab. Med. 2010, 48, 989-998
5. Jain, R. K.; Stylianopoulos, T. Delivering Nanomedicine to Solid Tumors Nat. Rev. Clin. Oncol. 2010, 7, 653-664
6. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
7. Patil, R.; Portilla-Arias, J.; Ding, H.; Inoue, S.; Konda, B.; Hu, J.; Wawrowsky, K. A.; Shin, P. K.; Black, K. L.; Holler, E. et al. Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(β-L-malic acid) Pharm. Res. 2010, 27, 2317-2329
8. Mrugala, M. M.; Chamberlain, M. C. Mechanisms of Disease: Temozolomide and Glioblastoma-Look to the Future Nat. Clin. Pract. Oncol. 2008, 5, 476-486
9. 6-Methylguanine-DNA Methyltransferase in Resistance of Human Brain Tumor Cell Lines to the Clinically Relevant Methylating Agents Temozolomide and Streptozotocin Clin. Cancer Res. 1996, 2, 735-741
10. 6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines Clin. Cancer Res. 2005, 11, 2747-2755
11. Bobola, M. S.; Kolstoe, D. D.; Blank, A.; Silber, J. R. Minimally Cytotoxic Doses of Temozolomide Produce Radiosensitization in Human Glioblastoma Cells Regardless of Mgmt Expression Mol. Cancer Ther. 2010, 9, 1208-1218
12. Silber, J. R.; Bobola, M. S.; Blank, A.; Schoeler, K. D.; Haroldson, P. D.; Huynh, M. B.; Kolstoe, D. D. The Apurinic/Apyrimidinic Endonuclease Activity of Ape1/Ref-1 Contributes to Human Glioma Cell Resistance to Alkylating Agents and Is Elevated by Oxidative Stress Clin. Cancer Res. 2002, 8, 3008-3018
13. Bobola, M. S.; Varadarajan, S.; Smith, N. W.; Goff, R. D.; Kolstoe, D. D.; Blank, A.; Gold, B.; Silber, J. R. Human Glioma Cell Sensitivity to the Sequence-Specific Alkylating Agent Methyl-Lexitropsin Clin. Cancer Res. 2007, 13, 612-620
14. 6-Benzylguanine in Adults with Recurrent, Temozolomide-Resistant Malignant Glioma J. Clin. Oncol. 2009, 27, 1262-1267
15. 6-Benzylguanine and Time Course of Peripheral Blood Mononuclear Cell O6-Methylguanine-DNA Methyltransferase Inhibition in the Nonhuman Primate Cancer Res. 1995, 55, 4606-4610
16. 6-Benzylguanine in Rats and Its Metabolism by Rat Liver Microsomes Drug Metab. Dispos. 1995, 23, 1394-1399
17. Boiardi, A.; Eoli, M.; Salmaggi, A.; Lamperti, E.; Botturi, A.; Solari, A.; Di Meco, F.; Broggi, G.; Silvani, A. Local Drug Delivery in Recurrent Malignant Gliomas Neurol. Sci. 2005, 26, s37-s39
18. Wang, P. P.; Frazier, J.; Brem, H. Local Drug Delivery to the Brain Adv. Drug Delivery Rev. 2002, 54, 987-1013
19. Allhenn, D.; Shetab Boushehri, M. A.; Lamprecht, A. Drug Delivery Strategies for the Treatment of Malignant Gliomas Int. J. Pharm. 2012, 436, 299-310
20. Juratli, T. A.; Schackert, G.; Krex, D. Current Status of Local Therapy in Malignant Gliomas-A Clinical Review of Three Selected Approaches Pharmacol. Ther. 2013, 139, 341-358
21. Allard, E.; Passirani, C.; Benoit, J.-P. Convection-Enhanced Delivery of Nanocarriers for the Treatment of Brain Tumors Biomaterials 2009, 30, 2302-2318
22. Saito, R.; Krauze, M. T.; Noble, C. O.; Tamas, M.; Drummond, D. C.; Kirpotin, D. B.; Berger, M. S.; Park, J. W.; Bankiewicz, K. S. Tissue Affinity of the Infusate Affects the Distribution Volume During Convection-Enhanced Delivery into Rodent Brains: Implications for Local Drug Delivery J. Neurosci. Methods 2006, 154, 225-232
23. Sun, C.; Du, K.; Fang, C.; Bhattarai, N.; Veiseh, O.; Kievit, F.; Stephen, Z.; Lee, D.; Ellenbogen, R. G.; Ratner, B. et al. PEG-Mediated Synthesis of Highly Dispersive Multifunctional Superparamagnetic Nanoparticles: Their Physicochemical Properties and Function in Vivo ACS Nano 2010, 4, 2402-2410
24. Sun, C.; Fang, C.; Stephen, Z.; Veiseh, O.; Hansen, S.; Lee, D.; Ellenbogen, R. G.; Olson, J.; Zhang, M. Tumor-Targeted Drug Delivery and Mri Contrast Enhancement by Chlorotoxin-Conjugated Iron Oxide Nanoparticles Nanomed. 2008, 3, 495-505
25. Veiseh, O.; Sun, C.; Fang, C.; Bhattarai, N.; Gunn, J.; Kievit, F.; Du, K.; Pullar, B.; Lee, D.; Ellenbogen, R. G. et al. Specific Targeting of Brain Tumors with an Optical/Magnetic Resonance Imaging Nanoprobe across the Blood-Brain Barrier Cancer Res. 2009, 69, 6200-6207
26. Longmire, M.; Choyke, P. L.; Kobayashi, H. Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and Caveats Nanomedicine 2008, 3, 703-717
27. MacKay, J. A.; Deen, D. F.; Szoka, F. C., Jr. Distribution in Brain of Liposomes after Convection Enhanced Delivery; Modulation by Particle Charge, Particle Diameter, and Presence of Steric Coating Brain Res. 2005, 1035, 139-153
28. Kim, B.; Han, G.; Toley, B. J.; Kim, C. K.; Rotello, V. M.; Forbes, N. S. Tuning Payload Delivery in Tumour Cylindroids Using Gold Nanoparticles Nat. Nanotechnol. 2010, 5, 465-472
29. Zhou, L.; He, B.; Zhang, F. Facile One-Pot Synthesis of Iron Oxide Nanoparticles Cross-Linked Magnetic Poly(vinyl alcohol) Gel Beads for Drug Delivery ACS Appl. Mater. Interfaces 2012, 4, 192-199
30. Luo, Z.; Cai, K.; Hu, Y.; Li, J.; Ding, X.; Zhang, B.; Xu, D.; Yang, W.; Liu, P. Redox-Responsive Molecular Nanoreservoirs for Controlled Intracellular Anticancer Drug Delivery Based on Magnetic Nanoparticles Adv. Mater. 2012, 24, 431-435
31. Ge, J.; Neofytou, E.; Cahill, T. J.; Beygui, R. E.; Zare, R. N. Drug Release from Electric-Field-Responsive Nanoparticles ACS Nano 2012, 6, 227-233
32. Caldorera-Moore, M. E.; Liechty, W. B.; Peppas, N. A. Responsive Theranostic Systems: Integration of Diagnostic Imaging Agents and Responsive Controlled Release Drug Delivery Carriers Acc. Chem. Res. 2011, 44, 1061-1070
33. Feener, E. P.; Shen, W. C.; Ryser, H. J. Cleavage of Disulfide Bonds in Endocytosed Macromolecules. A Processing Not Associated with Lysosomes or Endosomes J. Biol. Chem. 1990, 265, 18780-18785
34. Veiseh, M.; Gabikian, P.; Bahrami, S. B.; Veiseh, O.; Zhang, M.; Hackman, R. C.; Ravanpay, A. C.; Stroud, M. R.; Kusuma, Y.; Hansen, S. J. et al. Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci Cancer Res. 2007, 67, 6882-6888
35. Kesavan, K.; Ratliff, J.; Johnson, E. W.; Dahlberg, W.; Asara, J. M.; Misra, P.; Frangioni, J. V.; Jacoby, D. B. Annexin A2 Is a Molecular Target for Tm601, a Peptide with Tumor-Targeting and Anti-Angiogenic Effects J. Biol. Chem. 2010, 285, 4366-4374
36. Soroceanu, L.; Gillespie, Y.; Khazaeli, M. B.; Sontheimer, H. Use of Chlorotoxin for Targeting of Primary Brain Tumors Cancer Res. 1998, 58, 4871-4879
37. Lyons, S. A.; ONeal, J.; Sontheimer, H. Chlorotoxin, a Scorpion-Derived Peptide, Specifically Binds to Gliomas and Tumors of Neuroectodermal Origin Glia 2002, 39, 162-173
38. Veiseh, O.; Gunn, J. W.; Kievit, F. M.; Sun, C.; Fang, C.; Lee, J. S.; Zhang, M. Inhibition of Tumor-Cell Invasion with Chlorotoxin-Bound Superparamagnetic Nanoparticles Small 2009, 5, 256-264
39. Deshane, J.; Garner, C. C.; Sontheimer, H. Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2 J. Biol. Chem. 2003, 278, 4135-4144
40. Silber, J. R.; Bobola, M. S.; Blank, A.; Chamberlain, M. C. O6-Methylguanine-DNA Methyltransferase in Glioma Therapy: Promise and Problems Biochim. Biophys. Acta 2012, 1826, 71-82
41. Frosina, G. DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy Mol. Cancer Res. 2009, 7, 989-999
42. 6-Methylguanine: Implications for WRN Function DNA Repair 2004, 3, 629-638
43. Silber, J. R.; Bobola, M. S.; Ghatan, S.; Blank, A.; Kolstoe, D. D.; Berger, M. S. O6-Methylguanine-DNA Methyltransferase Activity in Adult Gliomas: Relation to Patient and Tumor Characteristics Cancer Res. 1998, 58, 1068-1073
44. Carlson, B. L.; Grogan, P. T.; Mladek, A. C.; Schroeder, M. A.; Kitange, G. J.; Decker, P. A.; Giannini, C.; Wu, W.; Ballman, K. A.; James, C. D. et al. Radiosensitizing Effects of Temozolomide Observed in Vivo Only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts Int. J. Radiat. Oncol., Biol., Phys. 2009, 75, 212-219
45. Frederick, L.; Wang, X. Y.; Eley, G.; James, C. D. Diversity and Frequency of Epidermal Growth Factor Receptor Mutations in Human Glioblastomas Cancer Res. 2000, 60, 1383-1387
46. Pegg, A. E. Mammalian O6-Alkylguanine-DNA Alkyltransferase: Regulation and Importance in Response to Alkylating Carcinogenic and Therapeutic Agents Cancer Res. 1990, 50, 6119-6129
47. Carlson, B. L.; Pokorny, J. L.; Schroeder, M. A.; Sarkaria, J. N. Establishment, Maintenance and in Vitro and in Vivo Applications of Primary Human Glioblastoma Multiforme (Gbm) Xenograft Models for Translational Biology Studies and Drug Discovery. Curr. Protoc. Pharmacol. 2011, Chapter 14, Unit 14.16.
48. Mardor, Y.; Rahav, O.; Zauberman, Y.; Lidar, Z.; Ocherashvilli, A.; Daniels, D.; Roth, Y.; Maier, S. E.; Orenstein, A.; Ram, Z. Convection-Enhanced Drug Delivery: Increased Efficacy and Magnetic Resonance Image Monitoring Cancer Res. 2005, 65, 6858-6863
49. Vogelbaum, M. A. Convection Enhanced Delivery for Treating Brain Tumors and Selected Neurological Disorders: Symposium Review J. Neurooncol. 2007, 83, 97-109
50. Juratli, T. A.; Schackert, G.; Krex, D. Current Status of Local Therapy in Malignant Gliomas-A Clinical Review of Three Selected Approaches Pharmacol. Ther. 2013, 139, 341-358
51. Lee, M. J. E.; Veiseh, O.; Bhattarai, N.; Sun, C.; Hansen, S. J.; Ditzler, S.; Knoblaugh, S.; Lee, D.; Ellenbogen, R.; Zhang, M. Q. et al. Rapid Pharmacokinetic and Biodistribution Studies Using Cholorotoxin-Conjugated Iron Oxide Nanoparticles: A Novel Non-Radioactive Method PLoS One 2010, 5 8
52. Moore, A.; Marecos, E.; Bogdanov, A., Jr.; Weissleder, R. Tumoral Distribution of Long-Circulating Dextran-Coated Iron Oxide Nanoparticles in a Rodent Model Radiology 2000, 214, 568-574
53. Medarova, Z.; Pham, W.; Farrar, C.; Petkova, V.; Moore, A. In Vivo Imaging of Sirna Delivery and Silencing in Tumors Nat. Med. 2007, 13, 372-377
54. Warren, K. E.; Gururangan, S.; Geyer, J. R.; McLendon, R. E.; Poussaint, T. Y.; Wallace, D.; Balis, F. M.; Berg, S. L.; Packer, R. J.; Goldman, S. et al. A Phase II Study of O6-Benzylguanine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Brainstem Gliomas: A Pediatric Brain Tumor Consortium Study J. Neuro-Oncol. 2012, 106, 643-649
55. NCI. Common Terminology Criteria for Adverse Events V3.0. http://ctep.cancer.gov/ProtocolDevelopment/electronic-applications/docs/ctcaev3.pdf (accessed March 2, 2012).
56. Burton, K. A Study of the Conditions and Mechanism of the Diphenylamine Reaction for the Colorimetric Estimation of Deoxyribonucleic Acid Biochem. J. 1956, 62, 315-323